» Articles » PMID: 30271205

Low Tumor Purity is Associated with Poor Prognosis, Heavy Mutation Burden, and Intense Immune Phenotype in Colon Cancer

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2018 Oct 2
PMID 30271205
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Tumor purity is defined as the proportion of cancer cells in the tumor tissue. The impact of tumor purity on colon cancer (CC) prognosis, genetic profile, and microenvironment has not been thoroughly accessed.

Materials And Methods: Clinical and transcriptomic data from three public datasets, GSE17536/17537, GSE39582, and TCGA, were retrospectively collected (n=1,248). Tumor purity of each sample was inferred by a computational method based on transcriptomic data. Survival-related analyses were performed on microarray dataset containing GSE17536/17537 and GSE39582 (n=794), whereas TCGA dataset was utilized for subsequent genomic analysis (n=454).

Results: Right-sided CC patients showed a significantly lower tumor purity. Low purity CC conferred worse survival, and tumor purity was identified as an independent prognostic factor. Moreover, high tumor purity CC patients benefited more from adjuvant chemotherapy. Subsequent genomic analysis found that the mutation burden was negatively associated with tumor purity, with only and significantly more mutated in high purity CC. However, no somatic copy number alteration event was correlated with tumor purity. Furthermore, immune-related pathways and immunotherapy-associated markers (programmed cell death protein 1 [PD-1], programmed death-ligand 1 [PD-L1], cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], Lymphocyte-activation gene 3 [LAG-3] and T-cell immunoglobulin and mucin-domain containing-3 [TIM-3]) were highly enriched in low purity samples. Notably, the relative proportion of M2 macrophages and neutrophils, which indicated worse survival in CC, was negatively associated with tumor purity.

Conclusion: Tumor purity exhibited potential value for CC prognostic stratification as well as adjuvant chemotherapy benefit prediction. The relative worse survival in low purity CC may attribute to higher mutation frequency in key pathways and purity-related microenvironmental changing.

Citing Articles

The Prognostic Value of Tumor-Associated Neutrophils in Colorectal Cancer: A Systematic Review and Meta-Analysis.

Jiang M, Zhang R, Huang M, Yang J, Liu Q, Zhao Z Cancer Med. 2025; 14(5):e70614.

PMID: 40013340 PMC: 11865885. DOI: 10.1002/cam4.70614.


Integrated analysis of single-cell and bulk transcriptomics reveals cellular subtypes and molecular features associated with osteosarcoma prognosis.

Liu F, Zhang T, Yang Y, Wang K, Wei J, Shi J BMC Cancer. 2025; 25(1):280.

PMID: 39962461 PMC: 11834279. DOI: 10.1186/s12885-025-13714-y.


Predicting patient outcomes with gene-expression biomarkers from colorectal cancer organoids and cell lines.

Razumovskaya A, Silkina M, Poloznikov A, Kulagin T, Raigorodskaya M, Gorban N Front Mol Biosci. 2025; 12:1531175.

PMID: 39886381 PMC: 11774744. DOI: 10.3389/fmolb.2025.1531175.


Construction and validation of a regulatory T cells-based classification of renal cell carcinoma: an integrated bioinformatic analysis and clinical cohort study.

Yao Y, Liu Y, Lu B, Ji G, Wang L, Dong K Cell Oncol (Dordr). 2024; .

PMID: 39714755 DOI: 10.1007/s13402-024-01030-9.


Identification of anoikis-related molecular patterns and the novel risk model to predict prognosis, tumor microenvironment infiltration and immunotherapy response in bladder cancer.

Zhu L, Xiao F, Hou Y, Huang S, Xu Y, Guo X Front Immunol. 2024; 15:1491808.

PMID: 39664392 PMC: 11631915. DOI: 10.3389/fimmu.2024.1491808.


References
1.
Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

2.
Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

3.
Park J, Richards C, McMillan D, Horgan P, Roxburgh C . The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Ann Oncol. 2014; 25(3):644-651. PMC: 4433525. DOI: 10.1093/annonc/mdt593. View

4.
Zou W, Wolchok J, Chen L . PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016; 8(328):328rv4. PMC: 4859220. DOI: 10.1126/scitranslmed.aad7118. View

5.
Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M . Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. Cancer Cell. 2016; 29(4):587-601. DOI: 10.1016/j.ccell.2016.03.005. View